-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, China Resources Shuanghe announced that .
Feng Yi, the chairman of the company, will no longer serve as a director, chairman and chairman of the strategy committee of the company's ninth board of directors since May 11, 2022 because he has reached the statutory retirement a.
According to the data, the company is a listed pharmaceutical manufacturing company, and its business covers new drug research and development, preparation production, drug sales, pharmaceutical equipment and API producti.
Feng Yi just turned 60 years old this ye.
Before that, Feng Yi served as the deputy general manager of the personnel department of China Resources (Group) and the deputy general manager of China Resources Snow Beer (Panjin), e.
He has worked in China Resources companies for many yea.
Since December 2018, Feng Yi has taken over the position of chairman of China Resources Shuanghe and has now served in the company for more than three yea.
During his tenure, China Resources Shuanghe developed steadily and continued to increase investment in research and developme.
In 2020, the company's R&D expenses will reach 291 million yuan, a year-on-year increase of 406%; in 2021, it will further increase to 410 million yuan, an increase of over 4
During the period, the company also passed the quality and efficacy consistency evaluation of a number of generic drugs, including montmorillonite powder, valsartan capsules, pitavastatin calcium tablets, irbesartan dispersible tablets, e.
On May 12, 2022, the company's Metronidazole tablets also received good ne.
Regarding Feng Yi's resignation, the company stated that it will not affect the normal operation of the company's board of directo.
The company will complete the by-election of the above-mentioned directors, the chairman of the strategy committee of the board of directors, and the election of the chairman as soon as possible in accordance with legal procedur.
From May 11 to the date of the election of the new chairman, Yu Shunting, the company's director and president, will perform the duties of chairman on his beha.
In fact, it is not only the China Resources Shuanghe family who have resigned as the chairm.
Since 2022, domestic pharmaceutical companies have been changing coaches, including Harbin Pharmaceutical, Heavy Pharmaceutical Holdings, China Resources Pharmaceutical, Dong'e Ejiao, e.
The reasons for resignation mainly include job changes, retirement, personal reasonse.
For example, on April 29, Haili Bio announced that the company's board of directors recently received a resignation report from the company's chairman, .
Zhang Y.
.
Zhang Yue requested to resign as the company's chairman and director, as well as the chairman and member of the strategy committee due to personal reaso.
, Membership of Nomination Committ.
On April 13, SINBON Pharma announced that, due to personal reasons, .
Anhualiu applied for his resignation as chairman, director, convener of the strategy committee of the board of directors, and member of the remuneration and appraisal committee of the eighth session of the board of directo.
At the end of March, Hainan Haiyao announced that the board of directors of the company received a written resignation application report from the chairman of the company, .
Pan Dazhong on March 26, 202 .
Pan Dazhong was originally scheduled to serve until March 24, 2023, and is now applying for resignation due to retirement reaso.
The positions of the company's director, chairman, convener of the strategy committee of the board of directors and member of the nomination committ.
On March 11, Heavy Pharmaceutical Holdings announced that Liu Shaoyun had applied for his resignation as the company's chairman, director, member and convener of the strategic development and investment committee of the board of directors, and member of the nomination committee of the board of directors for personal reaso.
On February 12, Harbin Pharmaceutical .
, L.
announced that due to retirement, .
Zhang Zhenping resigned from the company's vice chairman, director, and member of the Remuneration and Assessment Committee, and would not hold any other positions in the company after his resignati.
On January 28, China Resources Pharma issued an announcement on changes in the chairman, general manager and directors, which mentioned that Han Yuewei would no longer serve as its director, chairman and legal representati.
On January 10, Dong’e Ejiao issued an announcement that Han Yuewei had applied to resign from the positions of chairman and director of the tenth board of directors and chairman of the strategy committee of the tenth board of directors due to job chang.
The industry said that the change of the chairman of a state-owned enterprise will have a relatively small impact on the company, but if the chairman of a private enterprise changes its coach, it may have a greater impact on the compa.
It can also be seen that the entire medical environment is surging and undergoing major chang.
Feng Yi, the chairman of the company, will no longer serve as a director, chairman and chairman of the strategy committee of the company's ninth board of directors since May 11, 2022 because he has reached the statutory retirement a.
According to the data, the company is a listed pharmaceutical manufacturing company, and its business covers new drug research and development, preparation production, drug sales, pharmaceutical equipment and API producti.
Feng Yi just turned 60 years old this ye.
Before that, Feng Yi served as the deputy general manager of the personnel department of China Resources (Group) and the deputy general manager of China Resources Snow Beer (Panjin), e.
He has worked in China Resources companies for many yea.
Since December 2018, Feng Yi has taken over the position of chairman of China Resources Shuanghe and has now served in the company for more than three yea.
During his tenure, China Resources Shuanghe developed steadily and continued to increase investment in research and developme.
In 2020, the company's R&D expenses will reach 291 million yuan, a year-on-year increase of 406%; in 2021, it will further increase to 410 million yuan, an increase of over 4
During the period, the company also passed the quality and efficacy consistency evaluation of a number of generic drugs, including montmorillonite powder, valsartan capsules, pitavastatin calcium tablets, irbesartan dispersible tablets, e.
On May 12, 2022, the company's Metronidazole tablets also received good ne.
Regarding Feng Yi's resignation, the company stated that it will not affect the normal operation of the company's board of directo.
The company will complete the by-election of the above-mentioned directors, the chairman of the strategy committee of the board of directors, and the election of the chairman as soon as possible in accordance with legal procedur.
From May 11 to the date of the election of the new chairman, Yu Shunting, the company's director and president, will perform the duties of chairman on his beha.
In fact, it is not only the China Resources Shuanghe family who have resigned as the chairm.
Since 2022, domestic pharmaceutical companies have been changing coaches, including Harbin Pharmaceutical, Heavy Pharmaceutical Holdings, China Resources Pharmaceutical, Dong'e Ejiao, e.
The reasons for resignation mainly include job changes, retirement, personal reasonse.
For example, on April 29, Haili Bio announced that the company's board of directors recently received a resignation report from the company's chairman, .
Zhang Y.
.
Zhang Yue requested to resign as the company's chairman and director, as well as the chairman and member of the strategy committee due to personal reaso.
, Membership of Nomination Committ.
On April 13, SINBON Pharma announced that, due to personal reasons, .
Anhualiu applied for his resignation as chairman, director, convener of the strategy committee of the board of directors, and member of the remuneration and appraisal committee of the eighth session of the board of directo.
At the end of March, Hainan Haiyao announced that the board of directors of the company received a written resignation application report from the chairman of the company, .
Pan Dazhong on March 26, 202 .
Pan Dazhong was originally scheduled to serve until March 24, 2023, and is now applying for resignation due to retirement reaso.
The positions of the company's director, chairman, convener of the strategy committee of the board of directors and member of the nomination committ.
On March 11, Heavy Pharmaceutical Holdings announced that Liu Shaoyun had applied for his resignation as the company's chairman, director, member and convener of the strategic development and investment committee of the board of directors, and member of the nomination committee of the board of directors for personal reaso.
On February 12, Harbin Pharmaceutical .
, L.
announced that due to retirement, .
Zhang Zhenping resigned from the company's vice chairman, director, and member of the Remuneration and Assessment Committee, and would not hold any other positions in the company after his resignati.
On January 28, China Resources Pharma issued an announcement on changes in the chairman, general manager and directors, which mentioned that Han Yuewei would no longer serve as its director, chairman and legal representati.
On January 10, Dong’e Ejiao issued an announcement that Han Yuewei had applied to resign from the positions of chairman and director of the tenth board of directors and chairman of the strategy committee of the tenth board of directors due to job chang.
The industry said that the change of the chairman of a state-owned enterprise will have a relatively small impact on the company, but if the chairman of a private enterprise changes its coach, it may have a greater impact on the compa.
It can also be seen that the entire medical environment is surging and undergoing major chang.
